Iopidine

Apraclonidine, the active ingredient in Iopidine, is a Alpha‑2 adrenergic agonist presented as a 0.5% w/v ophthalmic solution for ocular use. It reduces intra‑ocular pressure in patients with glaucoma, ocular hypertension, and after eye surgery.

GNH USA supplies Iopidine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iopidine is an ocular hypotensive agent used to manage conditions that involve elevated intra‑ocular pressure.

Glaucoma: lowers intra‑ocular pressure to help prevent optic nerve damage. Ocular hypertension: reduces elevated eye pressure to lower risk of progression to glaucoma. Post‑operative intra‑ocular pressure control: helps manage pressure spikes after eye surgery.

Iopidine may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Burning or stinging sensation upon instillation. - Redness of the conjunctiva. - Transient blurred vision. - Dry eye sensation. - Mild headache. - Punctate keratitis.

Serious or Rare Side Effects: - Severe allergic reaction (angio‑edema, anaphylaxis). - Persistent ocular inflammation or uveitis. - Systemic hypotension or bradycardia. - Acute angle‑closure glaucoma. - Vision loss. - Stevens‑Johnson syndrome.

Before using Iopidine, consider the following safety measures.

Dosage adjustment: follow prescriber instructions, especially in patients with severe ocular disease. Contraindication: avoid in patients with known hypersensitivity to apraclonidine. Caution in narrow‑angle glaucoma: monitor intra‑ocular pressure closely. Avoid use with MAO inhibitors: risk of hypertensive crisis. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature: keep in original container, protect from light and moisture.

Iopidine can interact with other medications; review the following categories.

Major Interactions (Avoid): - MAO inhibitors: may precipitate hypertensive crisis. - Non‑selective beta‑blockers: may diminish ocular hypotensive effect.

Moderate Interactions (Monitor Closely): - Systemic alpha‑2 agonists: additive systemic hypotensive effect. - Topical prostaglandin analogues: possible reduced efficacy. - Anticholinergic eye drops: may increase ocular irritation.